Shire: FDA extends Mesavance review period bby 90 days

GabrielMadway

SAN FRANCISCO (MarketWatch) -- Shire Plc
shpgyca:shqSHP, -0.43%
said Friday the Food and Drug Administration has extended the new drug application review period for Mesavance by 90 days. The FDA sought the extension to allow it additional time to review supplemental Phase I data recently submitted by Shire, the U.K.-based company said. The FDA has set a new action date for the application of Jan. 21, 2007. Mesavance is a treatment for ulcerative colitis.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.